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doi:10.1Objective: Achieving transmural tissue ablation might be necessary for successful treatment of atrial fibrilla-
tion. The purpose of this study was to evaluate the reproducibility of transmural left atrial ablation using
a high-intensity focused ultrasound energy system in a calf model.
Methods:Nine heparinized bovines underwent a beating-heart left atrial ablation with a single application of the
high-intensity focused ultrasound device. All animals were acutely killed, and the left atrium was fixed in for-
malin. Protocolized histological sections (5 mm) were obtained throughout each lesion and prepared with
Masson trichrome and hematoxylin and eosin staining. Measurements were performed on a total of 359 slides
from the 9 lesions. In addition, fresh left atrial tissues from 18 unused human donor hearts that did not meet the
criteria for cardiac transplantation were measured at the site where the high-intensity focused ultrasound device
is normally applied.
Results: Calf left atrial thickness ranged between 2.5 and 20.1 mm, with a mean of 9.10 mm. High-intensity
focused ultrasound ablation consistently produced a 100% transmural lesion in left atrial thickness up to
6 mm. In addition, a transmural lesion was observed in 91% of tissues that were up to 10 mm thick and in
85% that were up to 15 mm thick. Human left atrial thickness ranged between 1.2 to 6 mm, with a mean of
3.7 mm.
Conclusions:Calf left atrial thickness in this studywas greater than human left atrial thickness. Human left atrial
thickness is generally less than 6 mm, and in this range high-intensity focused ultrasound ablation achieved
100% transmurality. These histological results might correlate with a high success rate of atrial fibrillation
ablation by using the high-intensity focused ultrasound system. (J Thorac Cardiovasc Surg 2010;140:1381-7)/B
SSupplemental material is available online.
Atrial fibrillation (AF) is present in approximately 9% of
patients older than 70 years and has been recognized as
an independent risk factor for cardiovascular morbidity
and mortality.1 Reported freedom from AF with medical
management and catheter ablation techniques is inferior
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Ttinues to be the gold standard for the treatment of AF,
with 92% to 97% cure rates at 10 years of follow-up.2 How-
ever, this procedure has not been widely adopted because of
its technical complexity and because of the required addi-
tional cardiopulmonary bypass time. The identification of
trigger zones for AF,3 specifically around the pulmonary
vein orifices, has lead to the development of simpler, less in-
vasive procedures using different energy sources. Several
different energy sources applied endocardially, epicardially,
or both have been used for this purposewith variable results.
A common goal when developing new technologies for
atrial ablation has been to create transmural lesions similar
to what is obtained with the cut-and-sew Cox maze proce-
dure. Some of the challenges that these new technologies
need to overcome include the ability to ensure transmurality
without damage of the surrounding structures in the setting
of variations in thickness, fat content, and the cooling effect
of atrial blood flow. High-intensity focused ultrasound
(HIFU) is a young technology in the armamentarium for
AF ablation. Clinical trials performed in Europe4 and the
United States5 with HIFU in patients with AF undergoing
concomitant cardiac surgery have reported a rate of freedom
fromAF of 85% at 18 months of follow-up. However, a his-
tological analysis demonstrating the presence of transmuraldiovascular Surgery c Volume 140, Number 6 1381
Abbreviations and Acronyms
AF ¼ atrial fibrillation
HIFU ¼ high-intensity focused ultrasound
LA ¼ left atrium
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Slesions with HIFU had not yet been published. The purpose
of this study was to assess the safety and reproducibility of
transmural left atrial (LA) ablation with the Epicor LP
HIFU system (St Jude Medical, St Paul, Minn) in a calf
model.FIGURE 1. Sites of high-intensity focused ultrasound ablation. A, Posi-
tion of the Epicor UltraCinch LP. B, Position of the Epicor UltraWand LP.MATERIALS AND METHODS
Device Description
The Epicor Cardiac Ablation System has been previously described.4
Briefly, the system consists of the Ablation Control System generator,
a family of disposable ablation devices, and a set of accessories. The Ab-
lation Control System is a microprocessor-based unit that enables acoustic
power to be delivered to the heart from ultrasound transducers. The Ultra-
Cinch LP device is an array of multiple (7–13) ultrasound transducers
(cells) that is used to produce a transmural circumferential LA lesion, iso-
lating the posterior LA and all 4 pulmonary vein orifices. An additional
tool, the UltraWand LP, is a handheld ablation device with only 2 trans-
ducers for the epicardial creation of additional linear lesions, such as the
line to the mitral annulus. The UltraWand LP was used in this model to
assess the effect of HIFU energy applied over coronary vessels.
Animal Studies
The study was conducted at Duke University under approval of the In-
stitutional Animal Care and Use Committee. All animals received humane
care in compliance with the ‘‘Guide for the care and use of laboratory an-
imals.’’ Nine calves with a weight range of 63 to 114 kg were selected for
the study.
System Characteristics
The transducers comprising the UltraCinch LP are positioned on the
epicardium but separated from direct contact with the cardiac tissue by
a thin perforated membrane. Room temperature normal saline is circulated
between the membrane and the transducers during ablation to enhance
acoustic coupling and cooling. Each transducer (103 15 mm) is designed
to deliver HIFU energy up to a distance of 10 mm from its surface. Beyond
the focal point, the energy dissipates within the LA cavity without exposing
the surrounding structures to potential collateral damage. The proprietary
UltraCinch LP algorithm generated by the Ablation Control System uses
a combination of frequency, power, and duration at which the transducers
are activated and powered (from 3.8–6.4MHz and from 15–130W) to gen-
erate 3 sequential stages of ablation. The ablation process begins with the
deep ablation stage, during which the energy is deposited distally from the
transducer in the subendocardial zone, followed by the intermediate stage
in which energy is deposited in the midmyocardial layer, followed by the
surface stage for epicardial energy deposition. During the first 2 stages,
each transducer is activated sequentially, and the energy is pulsed, whereas
during the third stage, transducers are staged 3 at a time with continuous-
wave HIFU to eliminate any residual gap within the epicardium. The lesion
is thus built up from the endocardium back to the epicardium and is com-
plete within approximately 10 minutes. The UltraWand LP is activated in
a similar fashion but uses a single stage for the creation of linear lesions
during a shorter 80-second algorithm that was designed for a handheld
device.1382 The Journal of Thoracic and Cardiovascular SurSurgical Technique
The animals were anesthetized with isoflurane, and a median sternot-
omy was performed. The surgical ablation was executed as previously de-
scribed by Ninet and colleagues.4 The pericardium was opened, and the
pericardial reflections around both the superior vena cava and inferior
vena cava were dissected free to gain access to both the transverse and ob-
lique sinuses. A specially designed introducer sizer was passed behind the
superior vena cava into the transverse sinus and guided into the oblique si-
nus and beneath the inferior vena cava, thereby completely encircling all 4
pulmonary veins. The graduated introducer sizer was used to measure the
circumference of the LA to select the proper size of UltraCinch LP device.
The introducer was subsequently used to guide the UltraCinch LP around
the LA. The introducer was then removed, and the 2 ends of the UltraCinch
LP device were approximated with tourniquets placed on the appropriate
sutures at each end to snug the device securely around the LA (Figure 1,
A).A 7- or 8-cell Epicor UltraCinch LP device was used in all 7 cases. A
bolus of heparin (100 IU/kg) was administered before the ablation cycle
start, and a continuous saline infusion was set by gravity with a bag height
of 35 inches, which yields approximately 1.5 mL/min per cell of irrigation
into the membranes overlying the transducer cells. The ablation cycle was
then initiated and progressed automatically until the UltraCinch LP abla-
tion had been completed. Physiologic data were recorded during the abla-
tion run. An additional lesion placed over the coronary sinus was also
created epicardially with the UltraWand LP (Figure 1, B). A continuous
saline infusion was maintained at a rate of 120 mL/h during the UltraWand
LP ablation cycle.
Tissue Processing
All animals were killed at the end of the procedure, and the heart was
immediately explanted for macroscopic examination. The LA and addi-
tional cardiac tissue surrounding the UltraCinch LP and UltraWand LP
lesions was widely resected en block. Endocardial and epicardial surfacesgery c December 2010
Villamizar et al Evolving Technology/Basic Sciencewere examined for color, appearance, evidence of perforation or rupture,
presence of intramural hemorrhage, presence of endocardial thrombus,
integrity of the pulmonary vein wall, and the mitral valve apparatus. The
resected tissue was then fixed in 10% formalin until sectioning. The fixed
LA was radially sectioned into 8 blocks, approximately equivalent to the
locations of the individual device cells (see Figure E1). The wand lesion
was serially sectioned perpendicular to the coronary sinus. Five standard
5-mm sections were prepared from each block, alternating Masson tri-
chrome and hematoxylin and eosin staining, and additional sections were
prepared in the same manner until each block was completely sectioned.
All sections were examined, and measurements were taken from 2 separate
sections of each block by using an ocular micrometer.
Measurements
Measurements were obtained from a total of 359 slides. Tissue thickness
was measured at the site of the lesion. Lesion thickness was measured. In
addition, fat and myocardial thickness, which composed the lesion, was re-
corded. Lastly, any gap of uninjured tissue was measured. Lesion transmur-
ality was calculated by comparing lesion depth and total tissue thickness, as
shown in Figure 2.
Human Studies
Human hearts that did not meet criteria for cardiac transplantation were
procured after research consent was obtained from our local organ-
procurement organization. Hearts were procured in standard fashion
from donors in which the lungs were also not used for transplantation to
allow for dissection and isolation of 2 to 3 cm of each pulmonary vein.
The LAwas separated from the left ventricle at the atrioventricular groove
immediately above the mitral valve similar to the procurement of the bo-
vine LAs. Measurements were made with a micrometer adjacent to but 2
mm central to each of the 4 pulmonary veins in the perceived location of
the UltraCinch LP device. Three measurements were taken at each location
and averaged. Data are presented as means  standard errors of the mean.RESULTS
Animal Studies
Macroscopic examination. There was no evidence of per-
foration or rupture of the cardiac tissues subjected to abla-
tion in any of the 9 animals. Gross examination of the
UltraCinch LP application site revealed a wide, distinct,FIGURE 2. Histology of the high-intensity focused ultrasound lesionwith
total versus fat thickness measurement.
The Journal of Thoracic and Carcircumferential lesion on the epicardium with correspond-
ing linear tracts on the endocardial surface on inversion of
the specimen, indicating transmural penetration of the le-
sion (Figure 3, A). Importantly, there was no evidence of
LA endocardial injury distant to the lesion. No intramural
hemorrhage or endocardial thrombus was identified in any
of the 9 animals. The pulmonary vein wall and mitral valve
apparatus demonstrated freedom from any injury in all 9 an-
imals. Gross examination of the UltraWand LP application
site did not show evidence of acute cavitation, perforation,
thrombosis of epicardial coronary vessels, or other unin-
tended trauma to the target tissue.
Microscopic examination. Microscopically, the type of
injury caused by the Epicor UltraCinch LP device was char-
acterized by a wedge-shaped lesion with a wide base at the
epicardial surface that progressively narrowed to the endo-
cardial surface. The histologic features include edema, nu-
clear hyperchromasia, and contraction bands, which are
typical of irreversible myocardial injury (Figure 3, B).
Calf total LA thickness for all 359 slides ranged between
2.5 and 20.1 mm, with a mean of 9.10 mm. Adipose tissue
thickness at the lesion site ranged between 0 and 16 mm,FIGURE 3. Characteristics of Epicor UltraCinch LP ablation. A, Macro-
scopic examination. B, Microscopic examination.
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FIGURE 4. Percentage of transmural lesions in relation to distribution of total thickness and percentage of adipose tissue using the Epicor UltraCinch LP.
HIFU, High-intensity focused ultrasound.
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and percentage of adipose tissue for the entire cohort is rep-
resented in Figure 4. Seventy-one percent of the measured
slides contained LA tissue that was 10 mm or less in total
thickness, which is the greatest depth at which the HIFU
beam is focused.
The Epicor UltraCinch LP consistently produced a 100%
transmural lesion in LA thickness up to 6 mm, which in-
cludes adipose tissue of up to 2.7mm. In addition, a transmu-
ral lesion was observed in 91% of tissues that were up to 10
mm thick and in 85% of tissues that were up to 15 mm thick
(Figure 4). The greatest total tissue thickness that underwent
a 100% transmural lesion was 14.5 mm. The greatest total
adipose tissue that underwent a 100% transmural lesion
was 9.6mm.Nontransmural lesionswere not located at a de-
fined anatomic landmark in every animal norwas there a cor-
relation between nontransmural lesions and the cell number
within the Epicor UltraCinch LP. The amount of adipose tis-
sue present on the target LA did not appear to correlate with
lesion transmularity. In contrast, the shape of the target tis-
sue and the orientation of the HIFU lesion (the direction of
the wedge-shaped lesion) seemed to play an important role
in obtaining transmurality (see Figure E2).
All nerve bundles identified within the HIFU beam ap-
peared irreversibly injured independent of size or tissue
depth (see Figure E3).
The Epicor UltraWand LP lesion was microscopically
similar to the UltraCinch LP lesion. No thrombosis was
seen inside the coronary sinus or circumflex artery over
which the Epicor UltraWand LP was applied. However,
there is some evidence of insult to smaller vessels that1384 The Journal of Thoracic and Cardiovascular Surcannot be fully characterized. The endothelial cell nuclei
are rounded, enlarged, and protrude into the lumen; these
are characteristic features of injured or reactive endothelial
cells. There are no specific histologic features that allow dif-
ferentiation between reversible versus irreversible endothe-
lial cell injury. It should be noted that no injury to the
circumflex artery or other nearby vessels has been observed
in chronic human studies extending as far out as 18 months
after the procedure.5,6
Human Studies
To determine the relationship of the calf model to adult
human LA thickness, we also measured LA thickness in
18 adult human unused donor hearts. The average age of
hearts examined was 51.8  4.6 years, and 28% had a his-
tory of cardiovascular disease. The mean human LA thick-
ness was 3.7 mm, with a range of 1.2 mm to a maximum
thickness of 6 mm.
DISCUSSION
AF is a significant cause of cardiovascular morbidity and
mortality.1 The success rate of medical therapy and catheter
ablation remains suboptimal. The cut-and-sew Cox maze III
surgical procedure has proved to be very effective but still
carries a significant risk for complications and is technically
challenging.2 Thedevelopment of new technologies to repro-
duce the outcomes obtainedwith the Coxmaze III procedure
but tominimize risks is an area of active investigation. Alter-
native energy sources used to treat AF include hypothermic
sources (cryoablation) and hyperthermic sources (radiofre-
quency, microwave, laser, and ultrasound ablation).gery c December 2010
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nary vein orifices as the trigger zones for AF, a great interest
has emerged to design ablation devices capable of isolating
these trigger zones. The Epicor LP HIFU system has been
designed to electrically isolate these areas in a safe and
reproducible manner.
Although the necessity to achieve conduction block
acutely is still a debatable topic, mature transmural lesions
will always result in chronic electrical block. Accordingly,
the only guarantee of long-term effectiveness is a fully
transmural lesion. For instance, Melby and associates6
have shown that AF can conduct through gaps of 1 mm or
greater in ablation lines. Furthermore, gaps along the lines
of prior ablation have been identified in patients with unsuc-
cessful surgical ablation.7 One of the end points of this study
was to determine the presence of transmurality in the abla-
tions created with the Epicor LP HIFU system. A single epi-
cardial, beating-heart application of the Epicor UltraCinch
LP device was 100% effective in producing a transmural
lesion in calf atrial tissue up to 6 mm thick, which was the
maximal thickness of measured adult human LA.
Incomparison, animal studieswith different energy sources
have reportedawide range of lesion thickness in beating-heart
models (Table 1).8-14 Cryoablation has produced transmural
lesions in 25% to 100% of samples in beating-heart models
with a mean LA thickness of 2.0  0.3 mm.8 Transmularity
with microwave ablation has only been achieved in 20% to
46% of samples in beating-heart animal models with
a mean LA thickness of 2.62  1.31 mm.9-11 Only 1 study
has reported transmularity with a laser energy source for
surgical AF in beating hearts, which showed all lesions to
be transmural in dogs, with an average tissue thickness of
3.62  1.50 mm (range, 0.95–7.06 mm).12 Bipolar radiofre-
quency clamp devices have been shown to create transmural
lesions in 92% to 100% of samples in beating-heart animal
models.13,14 However, the average tissue thickness was
4.2  0.1 mm in the swine model13 and 1.9  1.1 mm in
the sheep model.14 In this study we tested the HIFU product
in an animal model with much greater LA thickness relative
to other beating-heart models and with only a single applica-
tion, yet the experimental lesions in this study were deeper
than those observed in the other models.TABLE 1. Transmurality in beating-heart models
Study Energy source Anim
Doll and coworkers,8 2003 Cryoablation D
Van Brakel and coworkers,9 2004 Epicardial microwave D
Melby and coworkers,10 2006 Epicardial microwave
Gaynor and coworkers,11 2006 Epicardial microwave
Williams and coworkers,12 2006 Laser D
Melby and coworkers,13 2006 Bipolar RF
Bugge and coworkers,14 2005 Bipolar RF S
Villamizar and coworkers, 2010 HIFU C
LA, Left atrial; NS, nonspecified; RF, radiofrequency; HIFU, high-intensity focused ultras
The Journal of Thoracic and CarIn our analysis of human LA thickness, we found that the
averagehumanLAmeasures 3.7mm(range, 1.2–6mm).Our
results are similar to those of other anatomic studies aimed to
define the human LA anatomy to provide a firm background
for the development of AF ablation techniques. Cabrera and
coworkers15 reported a mean LA thickness of 2.8 1.1 mm
(range, 1.5–4.2 mm) between the orifices of the left pulmo-
nary veins and the os of the LA appendage in a total of 22 hu-
man hearts. Ho and colleagues16 found a mean LA thickness
of 3.7 0.6 mm (range, 2.9–4.5 mm) at the venoatrial junc-
tion of the left superior pulmonary vein in a total of 26 human
hearts. Sa´nchez-Quintana and associates17 showed a mean
LA thickness of 6.5  2.5 mm (range, 2.8–12 mm) at the
middle of the posterior atrial wall in a total of 15 cadavers.
These results suggest that the LA thickness of the canine,
swine, and sheep models in previous reports falls short of
maximal adult human LA thickness. Thus these models
might not be ideal for testing transmurality. In contrast, the
calf model provides a tissue thickness much greater than
human LA, as demonstrated by our findings.
Another advantage of the Epicor LP HIFU system is that
epicardial fat dissection is not necessary to achieve trans-
mural ablation. The average amount of adipose tissue in
the 9 animals included in this study was 3.10 mm (range,
0–16 mm). As an example, a lesion of 20.2 mm total thick-
ness with 16 mm of adipose tissue had a gap of only 0.55
mm of nonablated tissue after a single application of the Ep-
icor UltraCinch LP device, which demonstrates the efficacy
of HIFU to penetrate through fat. In contrast, Turek and co-
workers18 reported that microwave energy has diminished
penetration through adipose tissue. Assessment of adipose
tissue penetration by using other energy sources (cryoabla-
tion, radiofrequency ablation, and laser ablation) has not
been reported.
Some of the factors that might influence the depth of the
ablation achieved with alternative energy sources are anat-
omy, tissue composition, device sizing and position, and sa-
line flow rates. It did not appear that the amount of adipose
tissue present on the target LA significantly contributed to
the depth of the ablation in this model. However, the shape
of the target tissue and the orientation of the HIFU beam
seem to play an important role in obtaining transmurality.al model Mean LA thickness (mm) Transmurality (%)
og 2.0  0.3 96
og NS 33
Pig 2.62  1.31 46
Pig 2.88  0.4 20
og 3.62  1.5 100
Pig 4.2  0.1 100
heep 1.9  1.1 92
alf 9.10  2.6 84
ound.
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Epicor UltraCinch LP device. Because each cell measures
1.03 1.5 cm, it is possible to create a significant gap inter-
face between the cell surface and the epicardium when
oversizing the circumference around the pulmonary vein
orifices. On the other hand, undersizing might inhibit saline
flow to cool off the Epicor UltraCinch LP cells and main-
tain their integrity throughout the ablation cycle. Thus
appropriate sizing is important when using this epicardial
technology.
Another end point of this study was to determine the pres-
ence of vascular injury and thrombogenic complications in
areas where the Epicor LP HIFU system is applied. No
thrombogenic complications were appreciated with the
use of the Epicor LP HIFU system in this study. In compar-
ison, unipolar radiofrequency ablation has been associated
with thromboembolic complications,19 which appear to be
absent with the use of bipolar radiofrequency devices.20
There have also been reports of coronary artery stenosis
with microwave technology.21 Although experience has
shown that cryothermal energy appears to have no perma-
nent effects on valvular tissue or the coronary sinus, exper-
imental studies have shown late minimal hyperplasia of
coronary arteries.22-24 There are no reports about the
effect of laser ablation on the coronary vessels. The effect
of HIFU ablation on the small vessels found within the
HIFU beams appeared to be less destructive than has been
observed with other energy sources, such as microwave
ablation.18 The ability of HIFU to ablate tissue surrounding
the coronary arteries without damaging the arteries them-
selves has been attributed to the protective cooling effect
provided by the high blood flow through the coronary ar-
teries and the absence of acoustic heating of the blood.25
This study has some limitations that deserve discussion.
First, it uses a calf model to investigate the ablative charac-
teristics of a device designed to ablate human cardiac tissue.
It is unclear how healthy calf atrial tissue compares with
diseased human atria in patients with AF. Second, this study
represents an acute examination of the injured tissue; some
cells that appear dead might resurrect, and cells that appear
viable might die later. Anatomy or dimensions of the scar at
1 to 3 months might appear different, and therefore we are
planning more chronic studies. Third, conduction block was
not evaluated. The calf LA thickness was considerably
greater than the human LA thickness, and therefore gaps
were anticipated. Also, calves have a left superior vena
cava that traverses the site of the HIFU lesion, resulting in
greater total tissue thickness and preventing transmurality
at this site. Finally, acute conduction block might not corre-
late with late conduction block.
Despite these limitations, some assumptions could be
made from the observed results. The average calf LA thick-
ness in this study was 9.10 mm, and the range was between
2.5 and 20.1 mm. In contrast, the average LA in 18 human1386 The Journal of Thoracic and Cardiovascular Surhearts ranged between 1.2 and 6 mm, with a mean of 3.7
mm. HIFU ablation consistently produced a 100% trans-
mural lesion in LA tissue thickness up to 6 mm. Human
LA thickness is generally less than 6 mm, and in this range
HIFU ablation should achieve transmurality.
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FIGUREE1. Representation of how the fixed left atrium was divided into
8 sections (blocks) along the high-intensity focused ultrasound lesion to
obtain histology slides. Ao, Aorta; IVC, inferior vena cava; LAA, left atrial
appendage; LIPV, left inferior pulmonary vein; LSPV, left superior pulmo-
nary vein; MPA, main pulmonary artery; RIPV, right inferior pulmonary
vein; RSPV, right superior pulmonary vein; SVC, superior vena cava.
FIGURE E2. Oblique lesion presumably related to the shape of the target
tissue and the orientation of the high-intensity focused ultrasound lesion.
FIGURE E3. A, Irreversibly injured nerve bundle identified within the
high-intensity focused ultrasound beam caused by the Epicor UltraCinch
LP (hematoxylin and eosin stain). B, Ganglionic plexi ablated by the Epi-
cor UltraWand LP (Masson trichrome stain).
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